Skin is a vital barrier for the human body, protecting against external environmental influences and maintaining internal homeostasis. In addition, an imbalance of oxidative stress and antioxidant mechanisms can lead to skin-related diseases. Thus, for treating skin-related diseases, antioxidant therapy may be an important strategy to alleviate these symptoms. However, traditional drug therapies have limitations in treating these conditions, such as lack of lasting effect and insufficient skin permeability. Recently, nano-antioxidants, with their good permeability, sustained-release ability, multifunctionality, and other beneficial characteristics, have showed their advances in the exploration of skin-related diseases from research on safe therapies to clinical practice. Hereby, we review the latest research and advancements in nano-antioxidants for skin-related diseases. We categorize skin-related diseases into four main groups: skin inflammatory diseases, skin damage caused by ultraviolet rays, skin wound healing, and other skin-related conditions. Additionally, we summarize the prospects and potential future directions for nano-antioxidant drugs in treating skin-related diseases.
Background/Objectives: Bullous congenital ichthyosiform erythroderma (BCIE) is an inherited keratinization disorder caused by pathogenic variants in specific genes. Here, we report a pair of half-siblings with BCIE and tinea capitis due to Trichophyton rubrum (T. rubrum) and then review the species of ichthyosis previously reported with T. rubrum infection. Methods: We performed dermatological examination, fungal culture, and genetic analysis using whole-exome sequencing (WES) and blocker displacement amplification (BDA)-based Sanger sequencing. Both patients received oral terbinafine once daily and topical bifonazole gel for tinea capitis. Results: The pair of half-siblings had exhibited generalized scaling and hyperkeratosis since birth. Both siblings subsequently developed scalp pustules and hair loss for several months. Genetic analysis identified a pathogenic variant in the keratin 10 (KRT10) gene, confirming BCIE diagnosis. Additionally, fungal culture revealed T. rubrum infection. The patients responded positively to oral terbinafine antifungal treatment. Conclusions: This case highlights the potential susceptibility of patients with BCIE to fungal infections, warranting clinical vigilance. Furthermore, it demonstrates the utility of the BDA-based mutation detection method for diagnosing BCIE, suggesting its promise for advancing personalized diagnosis and management in hereditary skin diseases.